spacer
home > ebr > winter 2018 > regional requirements
PUBLICATIONS
European Biopharmaceutical Review

Regional Requirements

Globalisation has affected the life sciences and pharmaceutical industries just as much as it has other sectors, and a growing push to standardise submission formats has opened market opportunities for many life sciences companies. The common technical document (CTD) has already become the de facto standard in many regions as more and more countries respond to the ICH’s mission of greater harmonisation around the “interpretation and application of technical guidelines and requirements for pharmaceutical product registration” (1).

Regional Regulatory Climate

Today, most countries – either directly or through regional agencies – are members of the ICH or observe its guidelines. Through ongoing consultations between ICH and regulatory agencies, most regions of the world either have adopted – or are working towards meeting – the ICH guidelines centred on the areas of quality, safety, efficacy and multidisciplinary regulatory issues.

Even though most countries and regions are still paper-based, the push towards electronic submission is growing, and more countries are adopting or at least exploring electronic CTD initiatives. However, regional differences remain, even where strong alliances and a structured approach to regulatory submissions exist.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Kimty Bui-Van is head of regulatory and pharma services practice at ProductLife Group, where she is responsible for the coordination of all regulatory affairs activities undertaken on behalf of clients. She draws on nearly 20 years of experience in regulatory affairs, both within the industry and as a consultant, to guide clients through all aspects of regulatory affairs, including initial submissions, variations, renewals and product lifecycle management. Kimty has been instrumental in establishing a transformative approach to managing affiliate regulatory and pharmacovigilance activities globally on behalf of clients. 
spacer
Kimty Bui-Van
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Charles River Laboratories Expands Services for Early Discovery Screening

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the expansion of its service capabilities in early discovery screening. Charles River is the first contract research organization to offer clients access to Apricot Designs' Dual Arm (ADDA) system for high-throughput absorption, distribution, metabolism, and excretion (HT-ADME) to identify potential lead compounds in North America and Europe. Additionally, the Company has geographically expanded its pharmacokinetic (PK) capabilities at sites central to major pharmaceutical and biotechnology hubs.
More info >>

White Papers

The Power of Execution in Clinical Research

Medpace

Medpace, long known for its excellence in conducting Phase I-IV studies on a global platform, is particularly noted for its therapeutic excellence. When that expertise is combined with operational precision, the results are nothing short of stellar. The Medpace full-service outsourcing approach – combined with therapeutic expertise, regulatory know how, and global presence – delivers clinical studies with an industry recognized track record.
More info >>

 
Industry Events

On Helix 2018

10-11 July 2018, The Cambridge Building, Babraham Research Campus

ON Helix is a two-day event aimed at informing delegates of how to turn early stage inventions and ideas into innovative health treatments (new medicines, novel biomarkers, useful medical devices or improved medical practices).
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement